Domainex, a privately-owned drug discovery services company, is pleased to announce the appointment of Dr Bodo Spori as Head of Business Development for Europe.
His appointment reflects Domainex’s commitment to offering cutting-edge, integrated drug discovery services to an increasing number of customers across Europe and supporting the discovery of innovative new therapeutic candidates to treat unmet human diseases.
Bodo Spori is a German neuroscientist, born and raised in Belgium, with more than 13 years of experience in strategic business development roles.
He joins Domainex from Cyprotex, a subsidiary of Evotec, where he oversaw European and global sales initiatives in his role as VP of Business Development.
Previously, he worked as the Senior European Business Development lead at Scottish Biomedical.
"Domainex has an excellent reputation for delivering high quality drug discovery services to a global client base," said Dr Spori.
"Meeting Domainex’s management team and scientists clearly illustrated their expertise and collaborative approach, which underpins the 'every compound counts' philosophy driving their growth. I also sensed the strong commitment to innovation that has led to both the development of Domainex’s proprietary platforms, such as combinatorial domain hunting, as well as several candidate drugs."
"Spori's successful track record of identifying and forging strategic client collaborations, coupled with his experience of working in the fields of assay development, protein production, in vitro and in vivo pharmacology, compound profiling, screening and ADME, make him the ideal addition to our business development team."
"Spori will play a strategic role, building on our relationships with pharmaceutical and biotechnology companies across Europe and, via our services and expertise, help them advance their programmes towards development,” said Dr Tom Mander, COO of Domainex.
